https://orcid.org/0000-0002-1329-5288
Key points
Ipilimumab achieved an ORR of 23% in patients with multiply relapsed cHL, failing to meet the primary endpoint of the trial.
Expression of immune checkpoints within the cHL microenvironment may not be sufficient to predict efficacy of targeted immunotherapies.
This content is only available as a PDF.
Author notes
∗
These authors contributed equally
Data sharing: Data available for sharing by contacting the corresponding author.
© 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2025
